Multiple Sclerosis News

 
 
  • Epstein-Barr Virus a Likely Leading Cause of Multiple Sclerosis Epstein-Barr virus is the likely cause of multiple sclerosis, new research confirms. Investigators found the risk of MS increased 32-fold following EBV infection.
  • Little Evidence to Support Use of Pricey Repository Corticotropin Repository corticotropin costs much more than corticosteroids, but shows little clinical benefit over them, results of a scoping review suggest.
  • Half an Hour of Daily Sun Exposure Cuts MS Risk in Half Whereas previous research suggests sunlight can be protective against MS development, a new study shows even half an hour of daily sun exposure risk cuts MS risk in half in children and young adults.
  • Rituximab Better Than Natalizumab for MS Relapses? Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.
  • 'Glimpse of Hope' When Anti-CD20 Drugs Limit Vaccine Antibodies People taking a class of drugs known to limit the antibody response of the mRNA COVID-19 vaccines from Pfizer/BioNTech or Moderna may get some protection from another part of the immune system, according to a small study.
  • Alert Diroximel Fumarate (Vumerity) Cleared for MS in Europe Diroximel fumarate is similar to dimethyl fumarate (Tecfidera) in efficacy but has a unique chemical structure that may induce less GI irritation.
  • Brain Rhythm Predicts Response to DBS for Severe Depression Changes in brain beta rhythm with deep brain stimulation predict rapid and sustained decrease in depressive symptoms and could help optimize and personalize DBS treatment protocols.
  • CMSC 2021 Specialty Pharmacists May Speed Time to MS Treatment Specialty pharmacists play a key and growing role in helping patients navigate the complexities of initiating disease-modifying therapies for multiple sclerosis, resulting in earlier treatment, new data show.
  • CMSC 2021 B-Cell Repletion Common With MS Drug, but No Symptom Worsening Although some repletion of B cells occurs with the B-cell depleting MS drug ocrelizumab, the effect does not appear to be associated with symptom worsening or a 'wearing off' effect.
  • CMSC 2021 Brief, Automated Cognitive Test May Offer Key Advantages in MS A 30-minute, automated, iPad-based NIH Toolbox Cognitive Battery may offer some key advantages over gold standard tools, with automated scoring that accounts for race/ethnicity.
  • Childhood Infectious Mononucleosis a Risk Factor for Subsequent MS Diagnosis Infectious mononucleosis, an acute manifestation of the Epstein-Barr virus, is associated with an increased risk of developing multiple sclerosis if the infection occurs in childhood or adolescence, according to recent study findings.
  • CMSC 2021 Some MS Drugs Tied to Increased Psoriasis Risk 'People with MS and comorbid psoriasis may benefit from a careful consideration of disease-modifying therapy, specifically when B cell-depleting therapies are considered,' said coauthor Ahmed Obeidat, MD.
  • Babies Are Dying of Syphilis. It's 100% Preventable. The United States' inability to curb a treatable sexually transmitted disease shows the failures of a cash-strapped public health system. Increasingly, newborns are paying the price.
  • CMSC 2021 New Consensus Guideline on Clinical MRI Use in MS A new consensus guideline, created collaboratively between three international organizations, has been designed to boost much-needed protocol adherence during routine clinical use of MRI.
  • CMSC 2021 DMTs Often Switched During COVID, but Was It Necessary? Many US clinicians who treat for multiple sclerosis adjusted drug regimens during the pandemic's early months to lower risk for COVID-19 infection -- but they didn't need to, experts say.
  • CMSC 2021 Cannabis Use Common for MS-Related Spasticity Despite sweeping regulatory changes, usage of cannabis by patients with multiple sclerosis remains relatively steady, especially for treating spasticity, new research shows.
  • CMSC 2021 Two Diets Linked to Improved Cognition, Fatigue in MS Paleolithic elimination and low-saturated fat diets are associated with improvements in fatigue, cognitive dysfunction, and quality of life in patients with multiple sclerosis, new research suggests.
  • CMSC 2021 For MS Pain: Focus on Flexibility, Nondrug Treatments When treating pain in multiple sclerosis, a specialist is urging colleagues to think outside the box - especially since pain can evolve over time due to changes in MS and related conditions.
  • ECTRIMS 2021 Which Agent Best for Neuromyelitis Optica? A new indirect comparison of three new FDA-approved treatment options for aquaporin4+ neuromyelitis optica has suggested that eculizumab is the most effective. But many limitations have been raised.
  • CMSC 2021 Antipsychotic Effective for Steroid-Induced Psychosis in MS A popular antipsychotic calms patients with multiple sclerosis (MS) who develop psychiatric distress after taking corticosteroids, a new case review suggests.